Andreas Weiss

Author Reply to Peer Reviews of Sample-level modeling of single-cell data at scale with tinydenseR

Pedro Milanez‐Almeida, Daniela Schildknecht, Markus Linder, Saskia M Brachmann et autres

cn, de (code pays fourni par la source)

Sample-level modeling of single-cell data at scale with tinydenseR

Pedro Milanez‐Almeida, Daniela Schildknecht, Markus Linder, Saskia M. Brachmann et autres

Abstract Single-cell studies now routinely encompass hundreds of samples and millions of cells, offering unprecedented opportunities to link sample-level phenotypes with cellular and molecular states. However, current workflows often depend on cell-level inference and rigid clustering, which can distort significance and obscure …

us, ch (code pays fourni par la source)

Promise and Challenge of β-Lactone Electrophiles to Target Aspartate 12 of Mutant KRASG12D

Andrea Vaupel, Callum J. Dickson, Kim S. Beyer, Daniel Alexander Guthy et autres

. This endeavor was hampered by the lack of suitable electrophiles for the selective, covalent engagement of aspartate. Thanks to the recent discovery of β-lactone-bearing covalent inhibitors, new opportunities are emerging. Based on X-ray crystallographic insights and quantum chemical calculations, we herein …

cn, us (code pays fourni par la source)

Data from CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Anirudh Prahallad, Andreas Weiss, Hans Voshol, Gráinne Kerr et autres

Abstract Although KRASG12C inhibitors show clinical activity in patients with KRAS G12C mutated non–small cell lung cancer (NSCLC) and other solid tumor malignancies, response is limited by multiple mechanisms of resistance. The KRASG12C inhibitor JDQ443 shows enhanced preclinical antitumor activity combined with …

ch (code pays fourni par la source)

Supplementary Data from CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Anirudh Prahallad, Andreas Weiss, Hans Voshol, Gráinne Kerr et autres

Supplementary methods, tables and figures

Data from CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Anirudh Prahallad, Andreas Weiss, Hans Voshol, Gráinne Kerr et autres

Abstract Although KRASG12C inhibitors show clinical activity in patients with KRAS G12C mutated non–small cell lung cancer (NSCLC) and other solid tumor malignancies, response is limited by multiple mechanisms of resistance. The KRASG12C inhibitor JDQ443 shows enhanced preclinical antitumor activity combined with …

ch (code pays fourni par la source)

Supplementary Data from CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Anirudh Prahallad, Andreas Weiss, Hans Voshol, Gráinne Kerr et autres

Supplementary methods, tables and figures

CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer

Anirudh Prahallad, Andreas Weiss, Hans Voshol, Gráinne Kerr et autres

Although KRASG12C inhibitors show clinical activity in patients with KRAS G12C mutated non-small cell lung cancer (NSCLC) and other solid tumor malignancies, response is limited by multiple mechanisms of resistance. The KRASG12C inhibitor JDQ443 shows enhanced preclinical antitumor activity combined with the …

ch, us (code pays fourni par la source)

Proof-of-principle: targeted childhood leukemia prevention

César Cobaleda, Manuel R. Ramírez, Carolina Vicente‐Dueñas, Andreas Weiss et autres

Cancer is the most common cause of disease-related\nchildhood mortality in developed countries, with B-cell\nacute lymphoblastic leukemia (B-ALL) representing the\nmost frequent. A salient characteristic underlying some\ncases of childhood B-ALL is the presence of congenital\nmutations (either inherited or de novo) that are compatible\nwith normal …

es (code pays fourni par la source)

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS G12C for the Treatment of Solid Tumors

Edwige Lorthiois, Marc Gerspacher, Kim S. Beyer, Andrea Vaupel et autres

Rapid emergence of tumor resistance via RAS pathway reactivation has been reported from clinical studies of covalent KRAS G12C inhibitors. Thus, inhibitors with broad potential for combination treatment and distinct binding modes to overcome resistance mutations may prove beneficial. JDQ443 is an …

ch, us (code pays fourni par la source)

Abstract 4026: JDQ443, a covalent inhibitor of KRASG12C with a novel binding mode, shows broad antitumor activity in KRASG12C preclinical models as a single agent and in combination with inhibitors of SHP2, MEK or CDK4/6

Andreas Weiss, Hans Voshol, Diana Graus Porta, Carmine Fedele et autres

Abstract Background: Oncogenic mutations occurring in the KRAS component of the RAS/MAPK pathway slow nucleotide cycling between its active (GTP-bound) and inactive (GDP-bound) states, shifting it towards the active state and increasing oncogenic signaling. Among these mutations, the glycine-to-cysteine mutation of amino …

ch (code pays fourni par la source)

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Andreas Weiss, Edwige Lorthiois, Louise Barys, Kim S. Beyer et autres

Covalent inhibitors of KRASG12C have shown antitumor activity against advanced/metastatic KRASG12C-mutated cancers, though resistance emerges and additional strategies are needed to improve outcomes. JDQ443 is a structurally unique covalent inhibitor of GDP-bound KRASG12C that forms novel interactions with the switch II pocket. …

ch, us, jp (code pays fourni par la source)